US Patent Office clears patent covering IRLAB's IRL1117 drug candidate
The US Patent and Trademark Office issued a notice of allowance for a patent covering IRLAB's IRL1117 drug candidate. The patent is expected to stay in force into the early 2040s.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
According to Reuters, the United States Patent and Trademark Office (USPTO) has issued a notice of allowance for a patent covering IRLAB Therapeutics AB's drug candidate IRL1117.
The company stated that the patent is expected to remain in force until the early 2040s.
why it matters
The story is mainly corporate and concerns a single small pharmaceutical issuer. For the broader market its significance is limited, as it reflects intellectual property protection for an early-stage drug candidate.
tags
instruments
sources
- USPTO Issues Notice Of Allowance For Patent Covering Irlab's Drug Candidate IRL1117 — Reuters, 27 October 2026 at 06:03 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗